Astellas Pharma Inc. (OTCMKTS:ALPMY) Short Interest Down 69.8% in November

Astellas Pharma Inc. (OTCMKTS:ALPMY) was the recipient of a large decrease in short interest in November. As of November 30th, there was short interest totalling 30,400 shares, a decrease of 69.8% from the November 15th total of 100,500 shares. Based on an average trading volume of 494,200 shares, the short-interest ratio is currently 0.1 days.

Astellas Pharma Price Performance

ALPMY opened at $10.28 on Friday. The stock’s 50-day moving average price is $11.07 and its 200 day moving average price is $11.03. Astellas Pharma has a 12-month low of $9.15 and a 12-month high of $13.14. The company has a current ratio of 0.90, a quick ratio of 0.72 and a debt-to-equity ratio of 0.26. The firm has a market cap of $18.60 billion, a price-to-earnings ratio of 49.24 and a beta of 0.33.

Astellas Pharma (OTCMKTS:ALPMY) last issued its quarterly earnings results on Wednesday, October 30th. The company reported $0.13 earnings per share for the quarter. Astellas Pharma had a return on equity of 10.33% and a net margin of 3.26%. The company had revenue of $3.11 billion for the quarter. As a group, sell-side analysts expect that Astellas Pharma will post 0.61 earnings per share for the current year.

Astellas Pharma Company Profile

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.